SWOG
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Private, Subsidiary
- Established
- 1956-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.swog.org
Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors
Phase 3
Not yet recruiting
- Conditions
- Colorectal Cancer Stage IIColorectal Cancer Stage III
- First Posted Date
- 2025-06-13
- Last Posted Date
- 2025-06-19
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 1057
- Registration Number
- NCT07018869
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
Phase 3
Not yet recruiting
- Conditions
- Locally Advanced Pancreatic AdenocarcinomaMetastatic Pancreatic AdenocarcinomaStage III Pancreatic Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8Unresectable Pancreatic Adenocarcinoma
- Interventions
- Procedure: Biospecimen CollectionProcedure: Computed TomographyOther: Questionnaire Administration
- First Posted Date
- 2025-05-31
- Last Posted Date
- 2025-05-31
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 94
- Registration Number
- NCT06998940
Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
Phase 2
Not yet recruiting
- Conditions
- Lung Small Cell Carcinoma, I SubtypeLung Small Cell Carcinoma, N SubtypeLung Small Cell Carcinoma, P SubtypeExtensive Stage Lung Small Cell CarcinomaLung Small Cell Carcinoma, A Subtype
- Interventions
- Procedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Magnetic Resonance ImagingDrug: Platinum CompoundProcedure: Positron Emission TomographyRadiation: Thoracic Radiation Therapy
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 900
- Registration Number
- NCT06769126
Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula
Phase 3
Not yet recruiting
- Conditions
- Pancreatic CarcinomaPancreatic Neoplasm
- Interventions
- Procedure: Biospecimen CollectionProcedure: Distal PancreatectomyOther: Questionnaire AdministrationOther: Saline
- First Posted Date
- 2025-02-04
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 274
- Registration Number
- NCT06807437
Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia
Phase 2
Not yet recruiting
- Conditions
- CD19+ Acute LeukemiaPhiladelphia Chromosome Positive Acute Lymphoblastic Leukemia
- First Posted Date
- 2025-01-14
- Last Posted Date
- 2025-06-17
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 55
- Registration Number
- NCT06773936
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Phase 2
Recruiting
- Conditions
- Recurrent Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8
- Interventions
- Procedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Magnetic Resonance Imaging
- First Posted Date
- 2024-09-27
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 378
- Registration Number
- NCT06616584
- Locations
- πΊπΈ
Lewis Cancer and Research Pavilion at Saint Joseph's/Candler, Savannah, Georgia, United States
πΊπΈIllinois CancerCare-Bloomington, Bloomington, Illinois, United States
πΊπΈIllinois CancerCare-Canton, Canton, Illinois, United States
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
Phase 3
Recruiting
- Conditions
- Stage IVB Prostate Cancer AJCC v8Castration-Resistant Prostate Carcinoma
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone ScanProcedure: Chest RadiographyProcedure: Computed TomographyProcedure: Magnetic Resonance ImagingProcedure: Positron Emission Tomography
- First Posted Date
- 2024-06-24
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 528
- Registration Number
- NCT06470243
- Locations
- πΊπΈ
Highlands Oncology Group - Fayetteville, Fayetteville, Arkansas, United States
πΊπΈHighlands Oncology Group - Rogers, Rogers, Arkansas, United States
πΊπΈHighlands Oncology Group, Springdale, Arkansas, United States
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Phase 2
Recruiting
- Conditions
- Lung Non-Small Cell Carcinoma
- Interventions
- Procedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Magnetic Resonance Imaging
- First Posted Date
- 2023-11-03
- Last Posted Date
- 2025-02-19
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 88
- Registration Number
- NCT06116682
- Locations
- πΊπΈ
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
πΊπΈSutter Auburn Faith Hospital, Auburn, California, United States
πΊπΈAlta Bates Summit Medical Center-Herrick Campus, Berkeley, California, United States
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Phase 2
Recruiting
- Conditions
- Recurrent Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8
- Interventions
- Procedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: LymphoscintigraphyProcedure: Magnetic Resonance Imaging
- First Posted Date
- 2023-09-11
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 56
- Registration Number
- NCT06031688
- Locations
- πΊπΈ
Northwestern Medicine Cancer Center Kishwaukee, DeKalb, Illinois, United States
πΊπΈNorthwestern Medicine Cancer Center Delnor, Geneva, Illinois, United States
πΊπΈNorthwestern Medicine Glenview Outpatient Center, Glenview, Illinois, United States
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
Phase 3
Recruiting
- Conditions
- AL Amyloidosis
- Interventions
- Procedure: Biospecimen CollectionProcedure: Autologous Hematopoietic Stem Cell TransplantationProcedure: BiopsyProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Computed TomographyProcedure: Stem Cell IsolationProcedure: EchocardiographyOther: Survey AdministrationProcedure: Magnetic Resonance ImagingProcedure: Positron Emission Tomography
- First Posted Date
- 2023-09-05
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 338
- Registration Number
- NCT06022939
- Locations
- πΊπΈ
Smilow Cancer Hospital-Derby Care Center, Derby, Connecticut, United States
πΊπΈSmilow Cancer Hospital Care Center - Guilford, Guilford, Connecticut, United States
πΊπΈSmilow Cancer Hospital Care Center at Saint Francis, Hartford, Connecticut, United States